Table 2.
Results for primary and secondary outcomes in intention-to-treat analysis
| Outcomes | Atosiban (n=416) | Fenoterol (n=414) | Relative risk (95% CI) |
|---|---|---|---|
| Cephalic presentation 30 minutes after ECV (No; %)* | 140 (34) | 166 (40) | 0.73 (0.55 to 0.93) |
| Cephalic presentation at delivery (No; %)† | 139 (35) | 160 (40) | 0.86 (0.72 to 1.03) |
| Mode of delivery‡ | |||
| Vaginal delivery (No; %): | 163 (40) | 180 (45) | 0.89 (0.76 to 1.05) |
| Spontaneous | 146 | 167 | |
| Instrumental | 17 | 13 | |
| Caesarean delivery (No; %): | 240 (60) | 218 (55) | 1.09 (0.96 to 1.22) |
| Elective | 199 | 158 | |
| No progress of labour | 27 | 26 | |
| Suspected fetal distress | 4 | 21 | |
| Other | 10 | 13 |
ECV=external cephalic version.
*Imputation for primary outcome.
†Missing data: n=402 for atosiban, n=397 for fenoterol.
‡Missing data: n=403 for atosiban, n=398 for fenoterol.